AzTrials
AzTrials

DiabetesDIABESTNCT05488210

Study About Adherence and Tolerance of an Oral Nutritional Supplement (ONS) Specific for Diabetic Patient.

An observational study of Diabetes and Malnutrition, run by Instituto de Investigación Hospital Universitario La Paz at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Diabetes Mellitus (DM) is one of the most prevalent chronic diseases today, it is reaching epidemic proportions, mainly caused by the increase in type 2 diabetes (DM2).The foundation of any hypoglycemic treatment is based on a healthy diet, daily physical exercise and adequate health education with the collaboration… Read more about this study

Who is it for?
Ages 18 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Diabetes, Malnutrition
What is being tested?
FontActiv DiaBest HP/HC
How many people
24 participants
Where
1 siteSpain
Study dates
1 Jul 2022to 1 Jul 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Diabetic patients who present malnutrition through the GLIM criteria

Who may be able to join

  • Men and women enter 18 and 85 years old.
  • Patients with DM2 previously diagnosed and controlled.
  • Patients with malnutrition diagnosed according to GLIM criteria.
  • Patients who require taking ONS.
  • Patients willing to consume the ONS during the study period.
  • Patients with adequate cultural level and understanding of the clinical study.
  • Patients who agree to voluntarily participate in the study and who give their informed consent in writing.

Who cannot join

  • Subjects with enteral or parenteral nutrition.
  • Subjects with poorly controlled DM2.
  • Subjects with dementia, eating behavior disorders, history of serious neurological or psychiatric pathology that may interfere with adherence to the consumption of the ONS.
  • Subjects suffering from alcoholism or substance abuse that may interfere with adherence to the consumption of the ONS.
  • Subjects with a diagnosis of kidney or liver disease under pharmacological treatment.
  • Subjects with infections or any condition that interferes with nutrient digestion, absorption, metabolism, or excretion (including gastroparesis).
Show all 10Show fewer
  • Subjects with chronic gastrointestinal diseases that affect the digestion or absorption of nutrients.
  • Subjects with allergies or intolerances to any of the ingredients of the formula.
  • Subjects with socio-family problems that prevent them from participating in the study.
  • Pregnant or lactating women.

Trial locations and contacts

1 site in 1 country.

Bricia López-Plaza, PhD contact

917277000 ext. 442507

bricia.plaza@idipaz.es

Spain1 site, 1 recruiting
  • Samara Palma Milla

    Madrid, 28046

    Samara Palma Milla, PhD, 917277000 ext. 441209, samara.palma@salud.madrid.org

    samara.palma@salud.madrid.org

    Recruiting

Other trials in Spain

About this study

Official title: Study to Evaluate the Effect of Consuming an Oral Nutritional Supplement (ONS) Specifically for Diabetic Patients on Adherence and Gastrointestinal Tolerance and Nutritional Status in Patients With DM2 and Malnutrition

Diabetes Mellitus (DM) is one of the most prevalent chronic diseases today, it is reaching epidemic proportions, mainly caused by the increase in type 2 diabetes (DM2).The foundation of any hypoglycemic treatment is based on a healthy diet, daily physical exercise and adequate health education with the collaboration of the patient. Diet is sometimes the only necessary therapy since approximately 80% of patients with DM2 are usually overweight, what is mainly wanted with diet is to achieve normal blood glucose levels both fasting and in the postprandial phase. This diet must be a varied diet combining foods from the different food groups; however, carbohydrate control must be one of the key strategies for glycemic control. Currently, there is also talk of the concept of disease-related malnutrition (DRM). DRM is malnutrition associated with a pathological state, with the presence of inflammation being a key factor in determining its etiology. This inflammation can be chronic or acute depending on the type of pathology. Therefore, the fiber and carbohydrate composition of oral nutritional supplements are important for glycemic control, so a study is proposed to evaluate the effect of consuming a ONS hypercaloric/high-protein (HC/HP) with fiber, and enriched in calcium, Vitamin D and DHA on adherence and tolerance of the product and nutritional status in patients with DM2 and malnutrition.

Read the detailed description

Longitudinal, prospective exploratory study, to evaluate the effect of consuming an oral nutritional supplement (ONS) HC/HP with fiber, and enriched in calcium, Vitamin D and Docosahexaenoic acid (DHA) on adherence and tolerance of the product and nutritional status in patients with DM2 and malnutrition, in a period of 60 days. Twenty-four volunteers will be recruited at the La Paz University Hospital of Madrid. Participants should meet the next inclusion criteria: men and woman enter 18 and 85, with DM2 previously diagnosed and controlled, with malnutrition diagnosed according to the Global Leadership Initiative on Malnutrition (GLIM) criteria, who require taking ONS, willing to consume the ONS during the study and adequate cultural level and understanding of the clinical study. Follow up will include 4 individualized visits.

Being tested
FontActiv DiaBest HP/HC
Keywords
DM2, Oral nutritional supplement, Malnourished
Medical subject headings
Diabetes Mellitus, Malnutrition

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • FontActiv DiaBest HP/HCDietary supplement

    Also called Experimental

    Daily intake of two FontActiv DiaBest HP/HC during 2 months

Study groups in NCT05488210
Study groupRoleWhat they receive
Malnourished DM2 patientsDiabetic patients who present malnutrition through the GLIM criteria
Receives: Dietary Supplement: FontActiv DiaBest HP/HC

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Weight gain (kg)

    Changes in body weight. It is measured using a digital scale for clinical use (capacity 0-150 kg),with the person positioned with their back to the viewer, without shoes, wearing a minimum of warm clothing (pants and t-shirt), heels together, looking forward and posture straight body.

    Measured: Day 0, Day 60

  2. Fat mass (%)

    Changes in the percentage (%) of Fat Mass via bioelectrical impedance

    Measured: Day 0, Day 60

  3. Muscle mass (%)

    Changes in the percentage (%) of Muscle Mass via bioelectrical impedance

    Measured: Day 0, Day 60

Secondary outcomes (24)
  1. Waist circumference (cm)

    The subject assumes a position with arms crossed at the chest. The perimeter is taken at the narrowest level, between the lower costal margin (10th rib) and the iliac crest. The anthropometrist stands in front of the subject, who has his arms slightly abducted, to allow the waist to run around the abdomen. Values greater than 80 centimeters (women) and 94 centimeters (men) are considered a risk for cardiovascular diseases.

    Measured: Day 0, Day 60

  2. Body Mass Index (kg/m2)

    It is the relationship between the individual's body weight (kg) and height (m) squared: Weight/Height2. Values greater than 24,9 kg/m2 are considered as overweight

    Measured: Day 0, Day 60

  3. Extracellular water (%)

    Changes in the percentage (%) of Extracellular Water via bioelectrical impedance

    Measured: Day 0, Day 60

  4. Intracellular water (%)

    Changes in the percentage (%) of Intracellular Water via bioelectrical impedance

    Measured: Day 0, Day 60

  5. Total Body Water (%)

    Changes in the percentage (%) of Total Body Water via bioelectrical impedance

    Measured: Day 0, Day 60

  6. Phase angle (º)

    Changes in the phase angle (grades) via bioelectrical impedance

    Measured: Day 0, Day 60

  7. Body Cell Mass (%)

    Changes in the percentage (%) of Body Cell Mass via bioelectrical impedance

    Measured: Day 0, Day 60

  8. Albumin serum concentration (g/dL)

    Changes in serum albumin concentration. The normal range is 3.4 to 5.4 g/dL (34 to 54 g/L)

    Measured: Day 0, Day 60

  9. Prealbumin serum concentration (mg/dL)

    Changes in serum prealbumin concentration. Normal results in adults range between 15 and 36 milligrams per deciliter (mg/dL) or 150 and 360 milligrams per liter (mg/L)

    Measured: Day 0, Day 60

  10. Glucose serum concentration (mg/dL)

    Changes in fasting serum glucose concentration. The levels are between 74 and 100 mg/dL.

    Measured: Day 0, Day 60

  11. Insulin serum concentration (IU/mL)

    Changes in serum insulin levels. A basal insulin level between 5-25 IU/ml is considered normal, higher than 30 U/ml suggests insulin resistance. Insulin maximum value 6 to 8 times the basal value.

    Measured: Day 0, Day 60

  12. HbA1c serum concentration (%)

    Changes in the percentage of HbA1c. An HBA1c level of less than 5.7% is normal, 5.7 to 6.4% indicates prediabetes, and 6.5 or greater indicates diabetes. Within the prediabetes range (5.7 to 6.4%), the higher the A1c value, the greater the risk of developing type 2 diabetes

    Measured: Day 0, Day 60

  13. Total Cholesterol serum concentration (mg/dL)

    Changes in total cholesterol concentration. A concentration less than 200 mg/dL is recommended, with a normal upper limit between 200 and 239 mg/dL. Measurements above 240 mg/dL indicate excessive consumption through diet or familial hypercholesterolemia

    Measured: Day 0, Day 60

  14. Triglycerides serum concentration (mg/dL)

    Changes in triglyceride concentration. Normal values are less than 150 mg/dL; the upper limit is between 150 and 199 mg/dL. However, values between 200 and 499 mg/dl are considered high or very high (above 500 mg/dl).

    Measured: Day 0, Day 60

  15. LDL-cholesterol serum concentration (mg/dL)

    Changes in LDL-cholesterol concentration. Optimal levels are less than 100 mg/dL, although concentrations between 100 and 129 mg/dL are considered almost optimal. The upper limit of normal is between 130 and 159. Values between 160 and 189 mg/dL are considered high, and those above 190 mg/dL as very high.

    Measured: Day 0, Day 60

  16. HDL-cholesterol serum concentration (mg/dL)

    Changes in HDL-cholesterol concentration. Values above 60 mg/d Lare considered a protective factor against cardiovascular diseases.Concentrations between 40 and 59 mg/dL are correct, while values below 40 mg/dL are one of the main risk factors for cardiovascular disease.

    Measured: Day 0, Day 60

  17. Creatinine serum concentration (mg/dL)

    Changes in creatinine concentration. Normal values are 0.7 to 1.3 mg/dL (61.9 to 114.9 µmol/L) for men and 0.6 to 1.1 mg/dL (53 to 97.2 µmol/L) for women. Women often have lower creatinine levels than men, due to less muscle mass.

    Measured: Day 0, Day 60

  18. Urate serum concentration (mg/dL)

    Changes in urate concentration. Normal values are between 3.5 and 7.2 milligrams per deciliter (mg/dL).

    Measured: Day 0, Day 60

  19. Adherence to the Mediterranean Diet

    Questionnaire on Consumption Adherence to the Mediterranean Diet. The questionnaire consists of 14 questions with a variable score on different aspects of the diet and the Mediterranean pattern. A score less than 9 indicates poor adherence, while a score of 9 or more points indicates good adherence.

    Measured: Day 0, Day 60

  20. 24 hour food record questionnaire

    Questionnaire to find out the nutritional and dietary habits of each participant. The volunteer will write down all the food and drinks ingested over 1 day (24 hours). The answers will allow calculating the total amount of food consumed and calories ingested. In addition, the data will be evaluated quantitatively and qualitatively, classifying the diet in terms of diversity and balance following the recommendations of the Spanish Society of Community Nutrition (SENC 2016).

    Measured: Day 0, Day 60

  21. International Physical Activity Questionnaire (IPAQ)

    The questionnaire is divided into 4 categories of questions depending on the type of activity for which information is requested (vigorous, moderate, walking, sedentary). The quantitative results allow calculating the TOTAL Energy Metabolism Rate (MET) x minute/week for each subject. Qualitative results categorize the volunteers' physical activity into low activity (1), moderate activity (2), or vigorous activity (3).

    Measured: Day 0, Day 60

  22. Questionnaire on quality of life (EuroQoL 5D)

    The EuroQol 5D quality of life questionnaire will be used. The questionnaire is divided into two parts. In the first, questions are asked regarding mobility, personal care, daily activities and the presence of pain, discomfort, anxiety or depression. In the second part, the patient must use a visual analog health scale from 1 to 10 to indicate their subjective state of health, with 0 being the worst state of health imaginable and 10 being the best state of health imaginable.

    Measured: Day 0, Day 60

  23. Gastrointestinal symptoms rating scale (GSRS)

    The GSRS is a specific instrument for the assessment of digestive symptoms that includes 15 items grouped into 5 blocks based on the different gastrointestinal symptoms. The 5 groups of symptoms represent reflux, abdominal pain, indigestion, diarrhea and constipation. It has a score based on a Likert-type scale of 7 degrees, where 1 represents the most positive option and 7 the most negative.

    Measured: Day 0, Day 60

  24. Sensory perception

    The taste and olfactory sensory perception of the participants for the products will be evaluated by means of a questionnaire using Visual Analogue Scales (VAS) with a score of 0 to 10.

    Measured: Day 0, Day 60

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Aug 2022
  2. Study start1 Jul 2022
  3. Primary completion31 Dec 2022 (estimated)
  4. Study completion1 Jul 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
24 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05488210
Sponsor's protocol ID
PI-6092
Acronym
DIABEST
Status last verified
Apr 2022
First submitted
2 Aug 2022
Last updated
4 Aug 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes and Malnutrition, run by Instituto de Investigación Hospital Universitario La Paz at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Bricia López-Plaza, PhD (917277000 ext. 442507, bricia.plaza@idipaz.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Weight gain (kg) (time frame: Day 0, Day 60). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Aug 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in